Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Text message nudge could save thousands from pneumonia

NCT ID NCT07659470

Prevention Sponsor: Pablo Tomás Valenzuela García Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a simple WhatsApp message reminding people turning 65 in Chile to get their free pneumococcal vaccine can increase vaccination rates. Over 43,000 adults will be randomly assigned to receive the reminder or not, and researchers will track who gets vaccinated within 42 days. If successful, this low-cost approach could be used to boost vaccine coverage in other populations.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
WhatsApp text message reminder
What this could lead to
If it works, this could show that simple text reminders are a cheap, effective way to get more older adults vaccinated against pneumonia.
What could go wrong
This is a behavioral study, not a drug trial. The effect may be small, and results from Chile may not apply to other countries or age groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 43,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

64 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults born during the year 1961, turning 65 years of age in 2026 * Resident in Chile at the time of the study * Valid mobile phone number registered in the National Immunization Registry (RNI) Exclusion Criteria: * Record of pneumococcal vaccination in the National Immunization Registry (RNI). * Identified as deceased in the Chilean Civil Registry and Identification Service.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aged 65 years or older are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aged 65 years or older Health promotion Immunization programs Pneumococcal infections Reminder systems Text messaging (intervention) Vaccination coverage

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Immunization Program, Ministry of Health, Chile.

    Santiago, RM, 8320064, Chile

More trials for these conditions

Other studies related to the condition(s) this trial covers.